HALO · Halozyme Therapeutics, Inc.
Market Cap
$12.37B
Shares
113.50M
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Coverage backlog: 44 eligible filings and 0 covenant artifacts have no current-version terminal extraction result. This includes untouched sources and sources on the retry ladder.
No terminal debt extraction result is available yet; this is not evidence that the company has no debt.
Key facts
CIK
1159036
CUSIP
40637H109
13F (30d)
407 filings
386 filers
Visit website
Investor relations